Commenter: Anne-Charlotte Douard  
Affiliation: Access to Medicine Foundation

From: Anne-Charlotte Douard  
Sent: Monday, April 29, 2024 3:51 AM  
To: Pandemic Fund Consultations <pandemic_fund_consultations@worldbank.org>  
Subject: DEADLINE EXTENDED—8AM ET ON APRIL 29: The Pandemic Fund: Draft Strategic Plan for Public Consultations

Good morning,

Thank you for contacting the Access to Medicine Foundation about the World Bank Strategic Plan. Below is our feedback. Please don’t hesitate to reach out if you have any questions.

Kind regards,

Access to Medicine Foundation feedback:
1.2 Vision, mission, scope, and impact ambition
The Pandemic Fund’s impact ambition over its lifespan, as detailed in its Results Framework and Theory of Change, is to achieve a world with reduced health, social, and economic impact of pandemics. The Fund aims to help fill the gap in international funding for pandemic PPR in low- and middle-income countries and to protect communities around the world from future pandemics and other health threats. As the first and only multilateral, pooled financing mechanism dedicated specifically to mobilizing funds for pandemic PPR, it has an important opportunity and monumental task ahead of it.

Suggested addition:
The Pandemic Fund’s impact ambition over its lifespan, as detailed in its Results Framework and Theory of Change, is to achieve a world with reduced health, social, and economic impact of pandemics. The Fund aims to help fill the gap in international funding for pandemic PPR in low- and middle-income countries and to protect communities around the world from future pandemics and other health threats. As the first and only multilateral, pooled financing mechanism dedicated specifically to mobilizing funds for pandemic PPR, it has an important opportunity and monumental task ahead of it. The Fund also aims to ensure PPR products, such as vaccines, medicines and diagnostics, are promptly made accessible and affordable in low- and middle-income countries

2.4 Deep dive on underlying themes
“Health equity, including ensuring equitable access to pandemic PPR solutions and addressing disparities in health outcomes for all populations, regardless of background or status, is a cornerstone of effective and inclusive pandemic PPR.”

Suggested addition:
Health equity, including ensuring equitable timely and affordable access to pandemic PPR solutions and addressing disparities in health outcomes for all populations, regardless of background or status, is a cornerstone of effective and inclusive pandemic PPR.

4.2 Description of synergies with pandemic PPR funders
“The private sector will be another key partner for the Pandemic Fund in increasing the impact of its investments, both in terms of unlocking catalytic financing and leveraging their best practices and technical expertise. The Fund will consider employing innovative project structures and financing partnerships to enhance collaboration with the private sector.”

Suggested addition:
The private sector, including pharmaceutical companies, will be another key partner for the Pandemic Fund in increasing the impact of its investments, both in terms of unlocking catalytic
Commenter: Anne-Charlotte Douard
Affiliation: Access to Medicine Foundation

financing and leveraging their best practices and technical expertise. The Fund will consider employing innovative project structures and financing partnerships to enhance collaboration with the private sector. **The Fund will contractually bind the pharmaceutical companies it invests in to implement comprehensive access planning from an early stage (phase II) in all the pharmaceutical R&D projects it invests in. This aims to ensure the products developed are made accessible and affordable to all, including people living in low- and middle-countries.**

Anne-Charlotte Douard
Government Engagement & Policy Coordinator

**Access to Medicine Foundation**

www.accesstomedicinefoundation.org
Twitter: [Access to Medicine Foundation](#)
LinkedIn: [Access to Medicine Foundation](#)

**Our new report** puts the spotlight on the generics industry, with a first-of-its-kind assessment of what five major generic and biosimilar medicine manufacturers are doing to expand access to medicine.